News Center
SciBrunch Therapeutics Enters into Exclusive Global License Agreement with MSD for SPR2015, an Investigational Oral KRAS G12D (ON) InhibitorSHANGHAI, China, September 28, 2026 – SciBrunch Therapeutics Co., Ltd. (“SciBrunch”) and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), today announced that they have entered into an exclusi
SciBrunch Therapeutics Completes Over $35 Million Pre-A Round Financing, Totaling $65 Million in Two Recent RoundsSciBrunch Therapeutics announced the completion of an oversubscribed Pre-A round financing of over $35 million.
First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR1020SciBrunch Therapeutics announced that the Phase I/II clinical trial of SPR1020 for advanced solid tumors, co-led by the Cancer Hospital of the Chinese Academy of Medical Sciences and Harbin Medical
SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology DrugsSciBrunch Therapeutics recently announced the completion of an angel round financing of over RMB 200 million. The round was co-led by BioTrack Capital and Hankang Capital, with participation from Elik
- 1